Researchers examined trends in adherence to various treatment among patients with psoriasis using data from a large health insurance database. For which therapy had the highest odds for adherence, read more.

FDA Alerts

FDA Alerts
Monday, December 4, 2017
The FDA has expanded the approval of a psoriasis drug to now treat adults with psoriatic arthritis.
FDA Alerts
Monday, October 23, 2017
The FDA has approved extended use of a rheumatoid arthritis drug for the treatment of adult patients with active psoriatic arthritis or active ankylosing spondylitis.
FDA Alerts
Monday, October 16, 2017
The FDA has approved an expanded indication for ustekinumab (Stelara; Janssen) for the treatment of adolescent patients 12 years or older with moderate to severe plaque psoriasis.
FDA Alerts
Tuesday, August 29, 2017
The FDA has approved adalimumab-adbm (Cyltezo), a biosimilar of Humira (adalimumab), for the treatment of multiple inflammatory diseases.

News

News
Tuesday, May 22, 2018
The FDA has approved a label update for a biologic to include data on psoriasis with genital area involvement.
News
Friday, May 18, 2018
A recent randomized trial, conducted by Joel M. Gelfand, MD, and colleagues, examined the effects of 2 treatments on vascular inflammation in patients with psoriasis.
News
Tuesday, May 15, 2018
As a part of Psoriatic Arthritis (PsA) Action Month, the National Psoriasis Foundation launched a new awareness project and released 2 films that feature patients with PsA.
News
Friday, May 11, 2018
In a recent study, researchers investigated whether a biologic for psoriatic arthritis was associated with improvement in nail, along with skin, symptoms. For study results, read more.

NPF Endorsed Articles

NPF Endorsed Articles
Tuesday, December 22, 2015
Researchers conducted a systematic literature review of 73 published studies to identify factors associated with treatment non-adherence across diseases in rheumatology, gastroenterology and dermatology.   
NPF Endorsed Articles
Monday, December 21, 2015
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy. 
NPF Endorsed Articles
Monday, December 21, 2015
​The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology. 
NPF Endorsed Articles
Friday, December 18, 2015
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque psoriasis.

Research in Review

Research in Review
Tuesday, December 5, 2017
This 46-year-old woman had been doing well on adalimumab for the treatment of psoriasis for almost 2 years. She presented with what appeared to be a flare of her psoriasis.
Research in Review
Thursday, November 16, 2017
The condition is characterized by an acute, subacute, or chronic eruption of sterile pustules associated with erythema and inflammation. This patient’s case represents the annular variant characterized by pustules on the periphery of expanding erythematous plaques with central healing, most often localized to the trunk.
Research in Review
Friday, September 8, 2017
Starting a support group for patients with psoriasis has many benefits and some challenges, too.
Research in Review
Wednesday, August 9, 2017
Kaiser Permanente researcher and clinician has studied how inflammatory effects of psoriasis can impact the entire body.